Calendario de promoción Anixa Biosciences, Inc.
Horario avanzado
gráfico sencillo
Acerca de la empresa
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Más detalles| Выручка | 0.00025 |
|---|---|
| EBITDA | -0.0106 |
| Число акций ао | 0.03098 млрд |
| P/S | 313.47 |
| P/BV | 16.28 |
| EV/EBITDA | -7.07 |
| Цена ао | 3.13 |
| ISIN | US03528H1095 |
| Сайт | https://www.anixa.com |
| Валюта | usd |
| IPO date | 1987-01-01 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Cambio de precio por día: | -0.33% (3.03) |
|---|---|
| Cambio de precio por semana.: | -1.31% (3.06) |
| Cambio de precio por mes: | -9.85% (3.35) |
| Cambio de precio en 3 meses.: | +3.78% (2.91) |
| Cambio de precio en seis meses: | -3.21% (3.12) |
| Cambio de precio por año: | -7.65% (3.27) |
| Cambio de precio en 3 años.: | -31.98% (4.44) |
| Cambio de precio en 5 años.: | -23.74% (3.9602) |
| Cambio de precio desde principios de año.: | +4.14% (2.9) |
|
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
|||||||||||||||||||||||||||||||||||||
| Instituciones | Volumen | Compartir, % |
|---|---|---|
| Vanguard Group Inc | 1392906 | 4.37 |
| UBS Group AG | 580578 | 1.82 |
| Mission Wealth Management, LLC | 501168 | 1.57 |
| Laird Norton Trust Company, LLC | 368835 | 1.16 |
| Geode Capital Management, LLC | 312472 | 0.98 |
| Long Focus Capital Management, LLC | 165701 | 0.52 |
| Blackrock Inc. | 156797 | 0.49 |
| State Street Corporation | 108500 | 0.34 |
| Bank Of New York Mellon Corporation | 96654 | 0.3 |
| Susquehanna International Group, LLP | 73303 | 0.23 |
| ETF | Compartir, % | Rentabilidad del año, % | Dividendos, % |
|---|---|---|---|
| Dimensional U.S. Core Equity 2 ETF | 0.00005 | 30.755198832543 | 1.47098 |
| iShares Micro-Cap ETF | 0.02692 | 36.318555985322 | 1.54048 |
| Supervisor | Título profesional | Pago | año de nacimiento |
|---|---|---|---|
| Dr. Amit Kumar Ph.D. | CEO, Chairman & Co-Chair of CBAB | 1.29M | 1964 (60 años) |
| Mr. Michael J. Catelani CPA, MBA | President, COO, CFO & Corporate Secretary | 788.83k | 1967 (57 años) |
| Mr. John Roop | Senior Vice President of Engineering | 275k | 1950 (74 año) |
| Dr. Pamela D. Garzone Ph.D. | Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | 1955 (69 años) |
DIRECCIÓN: United States, San Jose. CA, 3150 Almaden Expressway - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.anixa.com
Sitio web: https://www.anixa.com
